While exercise scientists recommend activating mTOR to build muscle, longevity research shows that blocking mTOR with Rapamycin extends lifespan in multiple species.

As we age, our muscles over-activate mTOR in an attempt to maintain strength, which prevents the cellular cleanup process of autophagy from occurring.

Contrary to its reputation, studies suggest that when dosed correctly, Rapamycin does not appear to worsen the immune system in otherwise healthy people.

A new half-a-million-dollar Rapamycin study was successfully funded through community donations and sales of a product called microvitamin.

A new trial protocols participants to exercise on Mondays, Wednesdays, and Fridays, and then take Rapamycin on Saturday, separating the stimuli.

A new clinical trial's main objective is to first confirm that weekly Rapamycin does not worsen muscle performance in older adults who are exercising.

Out of all molecules currently being studied to extend lifespan, Rapamycin stands head and shoulders above the rest.